Immunocore
Immunocore is a biotechnology company that develops T cell receptor immunotherapies to treat cancer, infectious, and autoimmune diseases.
The UK Home Office lists Immunocore as a licensed sponsor (A-rated, Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. Home Office figures released under the Freedom of Information Act show Immunocore assigned 38 Certificates of Sponsorship in 2021–24 and 10 in 2025 for Skilled Worker and Global Business Mobility visas. We're showing 21 of their current openings.
Sponsor licence details
Sourced from the UK Home Office register of licensed sponsors.
Sponsorship history
Certificates of Sponsorship Immunocore assigned each year, from Home Office figures released under the Freedom of Information Act.
Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.
Licence timeline Pro
Every change we've seen on the Home Office register for Immunocore, and what its recent adverts say about sponsorship.
See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.
Unlock with ProAbout Immunocore
Immunocore is a biotechnology company focused on the development of T cell receptor (TCR) immunotherapies. The company researches, develops, and delivers immunomodulating medicines designed to treat cancer, infectious diseases, and autoimmune conditions.
Using its proprietary ImmTAX technology, Immunocore creates bispecific T cell receptor therapies that activate or tune the immune system to recognise and destroy diseased cells. Its pipeline includes therapies targeting solid tumors, such as its established treatment for metastatic uveal melanoma, as well as preclinical and clinical research programs spanning from laboratory discovery to patient delivery.
Open roles
21 live positions matched to this sponsor licence.